Abstract
The analysis of cell-free DNA in plasma, so called liquid biopsy, significantly improved the detectability of activating and resistance EGFR mutations in advanced non-small cell lung cancer (NSCLC) patients prior EGFR-TKI therapy and upon clinical progression, in particular when sufficient tumor tissue material is not available. Since the acquired resistance to EGFR-TKIs develops gradually under the inhibitor-specific selective pressure, the longitudinal analysis of mutated EGFR in both qualitative and quantitative manner may be more beneficial in term of the real-time treatment monitoring and early detection of resistance mutations.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
